Loading...

KRYS KRYSTAL BIOTECH INC Earnings Reports 8-K Filing

KRYS

KRYS

KRYSTAL BIOTECH INC

(KRYS)

2026 8-K

Financial Results Announced

Financial Results Announced

Financial Update

Positive Clinical Update

Director Resignation

Financial Results Announcement

Product Launch in Japan

Financial Statements

New Product Launches

New Product Launches

Product Expansion

Product Expansion

Clinical Trials

Financial Statements

Clinical Trials

New Product Launches

Financial Results

Clinical Results

Clinical Update

Financial Results

Positive Clinical Results

Financial Results Announcement

Annual Meeting of Stockholders

Presentation at ARVO Meeting

Financial Results Announcement

Financial Results Announcement

Earnings Reports

Resignation of Officer

Financial Results Announcement

Expansion in Oncology Pipeline

Securities Purchase Agreement

FDA Approval and Investor C...

Presentation of Data on Top...

Sales Agreement with Cowen ...

Financial Results Announcement

Data Presentation

Appointment of Director

Financial Results Announcement

FDA Review Period Extended

External Links:

On January 11, 2026, Krystal Biotech, Inc. announced that its net product revenues for VYJUVEK are expected to be between $106 million and $107 million for Q4 2025, and approximately $955 million in cash and investments as of December 31, 2025.

AI Assistant

KRYSTAL BIOTECH INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.